What type of study is this?

September 14, 2025

Real-World Data on Inotuzumab Ozogamicin for Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia: A GRELAL-Chile Study.

View Full Paper

Ask AI

Bookmark

Complete remission or remission with incomplete recovery was achieved in 74% of patients, showing effective treatment outcomes.
Among evaluated patients, 82% reached measurable residual disease below 0.01%, indicating positive treatment response.
Patients undergoing allogeneic hematopoietic stem cell transplantation after treatment had improved overall survival of 24.2 months compared to 5.2 months for those who did not.
Prognostic factors included comorbidities and high blast counts as adverse factors, while MRD negativity and Allo-HSCT were beneficial.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Observational analysis revealed high remission rates in patients with relapsed/refractory acute lymphoblastic leukemia, suggesting effective treatment options in Chile.

Cite This Study

Espinoza et al. (2025) studied this question.

synapsesocial.com/papers/68c6df6933b72be0b5e43bd8 https://doi.org/10.1002/cam4.71230

View Full Paper

Ask AI

Bookmark

Implication

Observational analysis revealed high remission rates in patients with relapsed/refractory acute lymphoblastic leukemia, suggesting effective treatment options in Chile.

Real-World Data on Inotuzumab Ozogamicin for Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia: A GRELAL-Chile Study.

Key Points

Discussion

Implication

Cite This Study

Real-World Data on Inotuzumab Ozogamicin for Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia: A GRELAL-Chile Study.

Key Points

Discussion

Implication

Cite This Study

Keep reading

Keep reading